HW
RCUS icon

Hancock Whitney’s Arcus Biosciences RCUS Stock Holding History

Hancock Whitney’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,945
Closed -$218K – 654
2023
Q1 		$218K Sell
11,945
-791
-6% -$15.1K 0.01% 602
2022
Q4 		$263K Buy
+12,736
New +$350K 0.01% 559

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Hancock Whitney's RCUS Position: Q2 2023 in Review

Hancock Whitney sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 11,945 shares — an estimated $218K sold.

Hancock Whitney first reported a position in RCUS in Q4 2022 and held it in 2 quarters. The position peaked at $263K in Q4 2022. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Hancock Whitney reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • Hancock Whitney sold 11,945 Arcus Biosciences shares in Q2 2023, an estimated $218K.
  • Hancock Whitney first reported a position in Arcus Biosciences in Q4 2022 and held it in 2 quarters.
  • Hancock Whitney's Arcus Biosciences position peaked at $263K in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Hancock Whitney's 13F filing for Q2 2023, filed 10 Aug 2023.